ALT
Price
$2.99
Change
-$0.06 (-1.97%)
Updated
Jul 13 closing price
Capitalization
581.48M
23 days until earnings call
Intraday BUY SELL Signals
INAB
Price
$1.34
Change
+$0.01 (+0.75%)
Updated
Jul 13 closing price
Capitalization
13.29M
23 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALT vs INAB

ALT vs INAB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ALT vs. INAB commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Buy and INAB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (ALT: $2.99 vs. INAB: $1.34)
Brand notoriety: ALT and INAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 43% vs. INAB: 127%
Market capitalization -- ALT: $581.48M vs. INAB: $13.29M
ALT [@Biotechnology] is valued at $581.48M. INAB’s [@Biotechnology] market capitalization is $13.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileINAB’s FA Score has 1 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • INAB’s FA Score: 1 green, 4 red.
According to our system of comparison, INAB is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 6 TA indicator(s) are bullish while INAB’s TA Score has 2 bullish TA indicator(s).

  • ALT’s TA Score: 6 bullish, 3 bearish.
  • INAB’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, ALT is a better buy in the short-term than INAB.

Price Growth

ALT (@Biotechnology) experienced а -2.92% price change this week, while INAB (@Biotechnology) price change was -6.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.21%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1806.27%.

Reported Earning Dates

ALT is expected to report earnings on Aug 06, 2026.

INAB is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (-3.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($581M) has a higher market cap than INAB($13.3M). ALT YTD gains are higher at: -17.175 vs. INAB (-42.735). INAB has higher annual earnings (EBITDA): -17.14M vs. ALT (-88.27M). ALT has more cash in the bank: 332M vs. INAB (21.9M). INAB has less debt than ALT: INAB (2.35M) vs ALT (35.8M). ALT has higher revenues than INAB: ALT (36K) vs INAB (0).
ALTINABALT / INAB
Capitalization581M13.3M4,368%
EBITDA-88.27M-17.14M515%
Gain YTD-17.175-42.73540%
P/E RatioN/AN/A-
Revenue36K0-
Total Cash332M21.9M1,516%
Total Debt35.8M2.35M1,521%
FUNDAMENTALS RATINGS
ALT: Fundamental Ratings
ALT
OUTLOOK RATING
1..100
17
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
59
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ALTINAB
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 29 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
78%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ALT
Daily Signal:
Gain/Loss:
INAB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCMCX30.16N/A
N/A
Goldman Sachs Mid Cap Value C
JUEMX28.62N/A
N/A
JPMorgan US Equity R6
SBEMX14.54N/A
N/A
Segall Bryant & Hamill Em Mkts Instl
HWMZX66.81N/A
N/A
Hotchkis & Wiley Mid Cap Value Z
CVTRX58.82-0.52
-0.88%
Calamos Growth & Income A

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with OGEN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then OGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
-1.97%
OGEN - ALT
54%
Loosely correlated
-2.75%
ACHV - ALT
45%
Loosely correlated
-0.16%
INDP - ALT
45%
Loosely correlated
N/A
XNCR - ALT
41%
Loosely correlated
-5.62%
DNLI - ALT
40%
Loosely correlated
+3.12%
More

INAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, INAB has been loosely correlated with FTH. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if INAB jumps, then FTH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INAB
1D Price
Change %
INAB100%
+0.75%
FTH - INAB
37%
Loosely correlated
-7.74%
CRDF - INAB
33%
Loosely correlated
+1.50%
ALT - INAB
33%
Poorly correlated
-1.97%
ACRV - INAB
32%
Poorly correlated
+1.02%
OVID - INAB
32%
Poorly correlated
-3.57%
More